Clovis has a plan to pry open the PARP market
Competition among a new class of cancer drugs called PARP inhibitors has been a story of pharma’s dominance over biotech. The pairing of AstraZeneca and Merck have consistently outperformed smaller rivals Clovis Oncology and Tesaro, and the gap is only widening.
But Clovis is angling to change those dynamics with its latest data. As STAT’s Adam Feuerstein reports, Clovis’ PARP inhibitor demonstrated a 44 percent tumor response rate in advanced prostate cancer no longer responsive to at least two prior therapies.
The company expects to make its case to the FDA by the end of next year. And if it succeeds, Clovis’ drug would be the first PARP approved for prostate cancer, giving it a shot at catching up with the market leader. Still, not everyone is convinced.
Read more.
But Clovis is angling to change those dynamics with its latest data. As STAT’s Adam Feuerstein reports, Clovis’ PARP inhibitor demonstrated a 44 percent tumor response rate in advanced prostate cancer no longer responsive to at least two prior therapies.
The company expects to make its case to the FDA by the end of next year. And if it succeeds, Clovis’ drug would be the first PARP approved for prostate cancer, giving it a shot at catching up with the market leader. Still, not everyone is convinced.
Read more.
.png)
No hay comentarios:
Publicar un comentario